Venatorx Pharmaceuticals Inc
CAGE Code: 61SY9
NCAGE Code: 61SY9
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 962754037
Summary
Venatorx Pharmaceuticals Inc is an Active Commercial Supplier with the Cage Code 61SY9 and is tracked by Dun & Bradstreet under DUNS Number 962754037..
Address
30 Spring Mill Dr
Malvern PA 19355-1200
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Lapidary Journal Inc Central Arkansas Trenching, Llc Delong Warren F Inc Bear-Ent, Llc Tjl Holdings, Inc. Potters Industries Inc Auto Environmental Technologies Ultronix Inc Wright And Son Service Co Skyline Toolworks Llc Laymens Retreat League Nocopi Technologies Inc Penn-Tech International, Inc. Beck B B Co Inc Liquid Nitrogen Processing Corp Perley-Halladay Associates Inc Sortins Technologies Inc Deltek Inc Malvern Cleaning Service J. M. Hunt Associates, Inc.
Frequently Asked Questions (FAQ) for CAGE 61SY9
- What is CAGE Code 61SY9?
- 61SY9 is the unique identifier used by NATO Organizations to reference the physical entity known as Venatorx Pharmaceuticals Inc located at 30 Spring Mill Dr, Malvern PA 19355-1200, United States.
- Who is CAGE Code 61SY9?
- 61SY9 refers to Venatorx Pharmaceuticals Inc located at 30 Spring Mill Dr, Malvern PA 19355-1200, United States.
- Where is CAGE Code 61SY9 Located?
- CAGE Code 61SY9 is located in Malvern, PA, USA.
Contracting History for CAGE 61SY9 Most Recent 25 Records
- 75A50123C00050
- No Cost Modification To Update Section G.3 Key Peronnel
- 20 Nov 2023
- No Cost Modification To Update Section G.3 Key Peronnel
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $20,321,717.00
- Department Of Health And Human Services (Hhs)
- 75A50123C00050
- Venatorx Pharmaceuticals: New Antibiotics To Treat Drug-Resistant Gram-Negative Bacteria Including Public Health Pathogens.
- 15 Sep 2023
- Venatorx Pharmaceuticals: New Antibiotics To Treat Drug-Resistant Gram-Negative Bacteria Including Public Health Pathogens.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $20,321,717.00
- Department Of Health And Human Services (Hhs)
- 75A50122C00080
- The Purpose Of This Modification Is To Update Article G.4. Key Personnel
- 1 Nov 2023
- The Purpose Of This Modification Is To Update Article G.4. Key Personnel
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $72,141,707.00
- Department Of Health And Human Services (Hhs)
- 75A50122C00080
- The Purpose Of This Modification Is To Update Article G.4. Key Personnel
- 12 Jun 2023
- The Purpose Of This Modification Is To Update Article G.4. Key Personnel
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $72,141,707.00
- Department Of Health And Human Services (Hhs)
- 75A50122C00080
- Venatorx Pharmaceuticals: Antibiotic For Amr And Biothreat Pathogens
- 27 Sep 2022
- Venatorx Pharmaceuticals: Antibiotic For Amr And Biothreat Pathogens
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $72,141,707.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- Non Beta-Lactam Inhibitors Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 16 May 2023
- Non Beta-Lactam Inhibitors Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $15,381,155.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 26 May 2022
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,183,132.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- Non Beta-Lactam Inhibitors Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 9 Jan 2023
- Non Beta-Lactam Inhibitors Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,669,276.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 16 Sep 2022
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,669,276.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- Non Beta-Lactam Inhibitors Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 29 Aug 2023
- Non Beta-Lactam Inhibitors Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $15,381,155.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 21 Dec 2021
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,229,128.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 29 Jun 2020
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,229,128.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00016
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- 11 Sep 2020
- To Advance A Novel Beta-Lactamase Inhibitor Of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,229,128.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Mod P00004 Is To Change Contracting Officer's Representative From Tina Guina, Ph.D. To Sheila Miknyoczki, Ph.D. In All Applicable Areas Of The Contract.
- 9 Jun 2020
- Mod P00004 Is To Change Contracting Officer's Representative From Tina Guina, Ph.D. To Sheila Miknyoczki, Ph.D. In All Applicable Areas Of The Contract.
- Office Of Acq&Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $55,358,255.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- This Product Is Being Developed For The Treatment Of The Following Indications: Complicated Urinary Tract Infections (Cutis), Hospital Acquired And Ventilator-Associated Pneumonia (Habp/Vabp), And Carbapenem Resistant Pathogen (Crp) Infections. A
- 16 Feb 2021
- This Product Is Being Developed For The Treatment Of The Following Indications: Complicated Urinary Tract Infections (Cutis), Hospital Acquired And Ventilator-Associated Pneumonia (Habp/Vabp), And Carbapenem Resistant Pathogen (Crp) Infections. A
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $55,358,255.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- The Purpose Of This Modification Is To Extend The Period Of Performance For Clin0007 Through September 30, 2024, To Complete The Manufacture And Release Of Three (3) Vnrx-5133 Drug Substance Process Validation Batches, At No Cost To The Government.
- 18 Dec 2023
- The Purpose Of This Modification Is To Extend The Period Of Performance For Clin0007 Through September 30, 2024, To Complete The Manufacture And Release Of Three (3) Vnrx-5133 Drug Substance Process Validation Batches, At No Cost To The Government.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $100,189,039.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Administrative Modification
- 31 Oct 2023
- Administrative Modification
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $100,189,039.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Nce On Clin 0002 Through 3/31/23 And Co Change
- 22 Mar 2022
- Nce On Clin 0002 Through 3/31/23 And Co Change
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $77,345,043.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Update Key Personnel And Provide Nces For Clins 0001, 0002, And 0003
- 12 Dec 2022
- Update Key Personnel And Provide Nces For Clins 0001, 0002, And 0003
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $91,820,899.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Add Additional Funding To Clin 0007, Update Period Of Performance, And Add Ipp Language
- 22 Sep 2022
- Add Additional Funding To Clin 0007, Update Period Of Performance, And Add Ipp Language
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $91,820,899.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- The Purpose Of This Modification Is To Update The Period Of Performance For Clin 0006 Through 6/30/2025.
- 12 Jun 2023
- The Purpose Of This Modification Is To Update The Period Of Performance For Clin 0006 Through 6/30/2025.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $91,820,899.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Mod P00003 Is To Exercise Clin 0002 (Option 1) And Clin 0006 (Option 5) Respectively For Phase 3 Habp/Vabp - Start Up And Cmc Drug Product Fss (Reg Batched). Additionally, $10 Million In Additional Supplemental Barda Funding And $4,500,000 In Venator
- 20 Apr 2020
- Mod P00003 Is To Exercise Clin 0002 (Option 1) And Clin 0006 (Option 5) Respectively For Phase 3 Habp/Vabp - Start Up And Cmc Drug Product Fss (Reg Batched). Additionally, $10 Million In Additional Supplemental Barda Funding And $4,500,000 In Venator
- Office Of Acq&Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $55,358,255.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Venatorx Pharmaceuticals, Inc.
- 17 Jul 2019
- Venatorx Pharmaceuticals, Inc.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $20,736,514.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- Incorporate Assignment Of Claims Per Contractor's Request, Nce For Clin0006, And Add Cs
- 29 Jul 2021
- Incorporate Assignment Of Claims Per Contractor's Request, Nce For Clin0006, And Add Cs
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $61,637,725.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00007
- The Purpose Of This Modification Is To Extend The Period Of Performance For Clin0009 From September 30, 2023, To March 31, 2024
- 13 Sep 2023
- The Purpose Of This Modification Is To Extend The Period Of Performance For Clin0009 From September 30, 2023, To March 31, 2024
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $100,189,039.00
- Department Of Health And Human Services (Hhs)